Chong Kun Dang faces Hanmi due to Rivaroxaban 2.5mg
By Lee, Tak-Sun | translator Choi HeeYoung
22.05.27 06:00:00
°¡³ª´Ù¶ó
0
Hanmi preoccupy generic (2.5mg) market alone by acquiring generic for exclusivity
Chong Kun Dang capsule formulation avoids generic for exclusivity, and patents seem to have been resolved
¡ãRiroxia 10mg, which was released five months before the expiration of the original material patent by Chong Kun Dang, dominated the generic market. Next month, capsule-type 2.5mg products will be listed, and it is expected to face off with Hanmi over the generic market
Chong Kun Dang anticoagulant Rivaroxaban 2.5mg will be listed as the second generic drug after Hanmi. Since Chong Kun Dang has shown extraordinary affection for anti-coagulation oral new drugs, it is expected that it will also focus its efforts on low dose Rivaroxaban products.According to the industry on the 22nd, Riroxia capsules 2.5mg will be listed next month. The original Rivaroxaban product is Bayer's Xarelto. However, 2.5mg product could not be released because it still has a patent for its product and a patent for its use, and Hanmi Pharmaceutical and SK Chemical acquired generic for exclusivity. There is also a difference in adaptation of the low dose (2.5 mg) and other doses. If 10, 15, and 2
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)